SCHEMBL19014651

SCHEMBL19014651

Cc1ccc(C)c(S(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.44
TSHR P16473 2/20 0.44
GAA P10253 1/20 0.44
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 3/20 0.41
KDM4E B2RXH2 1/20 0.41
F2 P00734 1/20 0.41
MAPT P10636 1/20 0.41
XBP1 P17861 1/20 0.41
EDNRB P24530 2/20 0.40
EDNRA P25101 2/20 0.40
UBE2N P61088 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13975628 0.83 ALDH1A1 (0.46) ALDH1A1TSHRGAALMNAKMT2A
SCHEMBL765764 0.82 EPAS1 (0.40) ALDH1A1TSHRLMNASMN1; SMN2HPGD
SCHEMBL8643794 0.81 EPAS1 (0.43) ALDH1A1KMT2AHTTKDM4EMAPT
SCHEMBL8643797 0.81 EPAS1 (0.43) ALDH1A1KMT2AHTTKDM4EMAPT
SCHEMBL24483952 0.78 ESPL1 (0.33) ALDH1A1LMNAPOLB
SCHEMBL19014702 0.78 PDE2A (0.36) ALDH1A1LMNAKMT2ASMN1; SMN2POLB
SCHEMBL24483959 0.78 ALDH1A1 (0.43) ALDH1A1LMNAPOLBHTT
SCHEMBL25087889 0.77 ALDH1A1 (0.39) ALDH1A1LMNAPOLB
SCHEMBL7112755 0.76 UBE2N (0.57) ALDH1A1TSHRGAALMNAKMT2A
SCHEMBL31125103 0.75 ALDH1A1 (0.60) ALDH1A1TSHRLMNASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2023-05-11 US disclosed
WO-2017101851-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. (US) 2017-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142274-A1 SUBSTITUTED ARYL COMPOUND RAD51, FANCI, BLM ALDH1A1 2893/4885TSHR 3887/4885GAA 4087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.